136 related articles for article (PubMed ID: 19173791)
1. Use of olopatadine ophthalmic solution and reactivity of histamine skin testing.
Jones JD; Temino VM; Dworski R; Anderson CK; Fahrenholz JM; An AQ
Allergy Asthma Proc; 2008; 29(6):636-9. PubMed ID: 19173791
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24-h period: a double-blind, randomized, cross-over, placebo-controlled comparison in skin responses induced by histamine iontophoresis.
Takeo T; Kasugai C; Tanaka R; Ando T; Ogawa A; Akita Y; Watanabe D
J Dermatol; 2013 Dec; 40(12):987-92. PubMed ID: 24303975
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study.
Yamamoto H; Yamada T; Kubo S; Osawa Y; Kimura Y; Oh M; Susuki D; Takabayashi T; Okamoto M; Fujieda S
Allergy Asthma Proc; 2010; 31(4):296-303. PubMed ID: 20819319
[TBL] [Abstract][Full Text] [Related]
5. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance.
Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2004 Sep; 29(5):526-32. PubMed ID: 15347340
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.
Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Gross RD; Turner FD; Wells DT; Bergamini MV; Robertson SM
Clin Ther; 2004 Aug; 26(8):1237-48. PubMed ID: 15476905
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
Deschenes J; Discepola M; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
[TBL] [Abstract][Full Text] [Related]
8. Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses.
Morita K; Koga T; Moroi Y; Urabe K; Furue M
J Dermatol; 2002 Nov; 29(11):709-12. PubMed ID: 12484432
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
[TBL] [Abstract][Full Text] [Related]
10. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM
Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis.
Meltzer EO; Blaiss M; Fairchild CJ
Allergy Asthma Proc; 2011; 32(3):213-20. PubMed ID: 21477426
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit.
Enomoto T; Lu HQ; Yin M; Sakoda T; Dake Y; Enomoto K; Ide T; Cheng L
J Investig Allergol Clin Immunol; 2009; 19(4):299-305. PubMed ID: 19639726
[TBL] [Abstract][Full Text] [Related]
15. Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
Kamei H; Isaji A; Noda Y; Ishikawa K; Senzaki K; Yamada K; Sugiura K; Tomita Y; Nabeshima T
Arch Dermatol Res; 2012 May; 304(4):263-72. PubMed ID: 22130869
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis.
Takahashi H; Zhang Y; Morita E
Arch Dermatol Res; 2008 Jul; 300(6):291-5. PubMed ID: 18305947
[TBL] [Abstract][Full Text] [Related]
19. [Intradermal tests using vasomotor agents in allergic rhinitis].
Milosević DN; Janosević LjB; Janosević SB
Srp Arh Celok Lek; 2000; 128(11-12):357-62. PubMed ID: 11337913
[TBL] [Abstract][Full Text] [Related]
20. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.
Abelson MB; Gomes PJ
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):453-61. PubMed ID: 18433347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
